These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 314982)

  • 1. Twice-daily dosing of enteric-coated aspirin in patients with rheumatic diseases.
    Bensen WG; Laskin CA; Paton TW; Little HA; Fam AG
    J Rheumatol; 1979; 6(3):351-9. PubMed ID: 314982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin dosing using 15 grain enteric coated tablets.
    Pollet S; White RH; Jang H; Yim CW; Feigal D
    J Rheumatol; 1985 Apr; 12(2):337-42. PubMed ID: 4032405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state plasma levels of salicylate in patients with rheumatoid arthritis: effects of dosing interval and tablet strength.
    Keystone EC; Paton TW; Littlejohn G; Verdejo A; Piper S; Wright LA; Goldsmith CH
    Can Med Assoc J; 1982 Aug; 127(4):283-6. PubMed ID: 7093867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analgesics; the use of aspirin in dogs; effects of tablet type and food intake on plasma salicylate level].
    Nap RC; Breen DJ; Lam TJ; Peters IO; Willemsen A; De Bruyne JJ
    Tijdschr Diergeneeskd; 1993 Jul; 118(13):439-42. PubMed ID: 8346511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double blind comparison of piroxicam and enteric coated ASA in rheumatoid arthritis. A Cooperative Multicenter Canadian trial.
    J Rheumatol; 1985 Feb; 12(1):68-77. PubMed ID: 3884806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal iatrogenic salicylate intoxication in a long-term user of enteric-coated aspirin.
    Shkrum MJ; Gay RM; Hudson P
    Arch Pathol Lab Med; 1989 Jan; 113(1):89-90. PubMed ID: 2910232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dosage effect of enteric-coated ASA on serum salicylate levels.
    Woodbury JF; Ahmad S
    N S Med Bull; 1973 Jun; 52(3):123-6. PubMed ID: 4584430
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.
    Schiff M; Hochberg MC; Oldenhof J; Brune K
    Curr Med Res Opin; 2009 Oct; 25(10):2471-7. PubMed ID: 19678751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets.
    Jung D; Schwartz KE
    Clin Ther; 1994; 16(6):923-9. PubMed ID: 7697688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
    Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
    J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled trial of enteric coated aspirin in coronary bypass graft patients. Effect on graft patency.
    Hockings BE; Ireland MA; Gotch-Martin KF; Taylor RR
    Med J Aust; 1993 Sep; 159(6):376-8. PubMed ID: 8377686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral venous plasma aspirin concentrations and platelet aggregation inhibition produced by enteric-coated aspirin formulations.
    Brandon RA; Emmett JA; Eadie MJ; Curran AC; Bunce IH
    Thromb Haemost; 1986 Apr; 55(2):222-7. PubMed ID: 3715789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
    Roberts D; Easter D; O'Bryan-Tear G
    Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absorption of acetylsalicylic acid from an enteric-coated formulation and the inhibition of thromboxane formation.
    Anttila M; Kahela P; Uotila P
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):88-92. PubMed ID: 3410591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability.
    Portek I; Graham G; Fleming A
    Med J Aust; 1981 Jul; 2(1):39-40. PubMed ID: 6974303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration.
    Savon JJ; Allen ML; DiMarino AJ; Hermann GA; Krum RP
    Am J Gastroenterol; 1995 Apr; 90(4):581-5. PubMed ID: 7717315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose evaluation of a new enteric-coated aspirin preparation.
    Paull P; Day R; Graham G; Champion D
    Med J Aust; 1976 Apr; 1(17):617-9. PubMed ID: 933973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enteric aspirin tablets and the salicylate concentration in the plasma in the morning].
    Laine V; Strandman D; Tikkanen R
    Lakartidningen; 1968 Sep; 65(39):3832-7 passim. PubMed ID: 5741894
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.
    Petroski D
    Am J Gastroenterol; 1986 Jan; 81(1):26-8. PubMed ID: 3942122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.